NOEMI
PUIG MORON
Investigadora desde 2015
Instituto de Investigación Biomédica de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (22)
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239
2021
-
Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
Modern Pathology, Vol. 34, Núm. 1, pp. 59-69
-
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
Cancers, Vol. 13, Núm. 7
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
2019
-
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Blood
-
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)
Leukemia
-
Distribution of subsets of blood monocytic cells throughout life
Journal of Allergy and Clinical Immunology, Vol. 144, Núm. 1, pp. 320-323.e6
-
Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma
HemaSphere, Vol. 3, Núm. 3
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal, Vol. 9, Núm. 4
2018
-
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Leukemia, Vol. 32, Núm. 11, pp. 2427-2434
-
Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study
Annals of Hematology, Vol. 97, Núm. 3, pp. 475-484
2017
-
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma
Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615
-
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Haematologica, Vol. 102, Núm. 5, pp. 922-931
2016
-
MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry
Cell Communication and Signaling, Vol. 14, Núm. 1
-
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Blood, Vol. 127, Núm. 4, pp. 420-425
2015
2014
-
Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction
Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234